Antiangiogenic activities of 2,5-dimethyl-celecoxib on the tumor vasculature

Jenilyn J. Virrey, Zhi Liu, Hee Yeon Cho, Adel Kardosh, Encouse B. Golden, Stan G. Louie, Kevin J. Gaffney, Nicos A. Petasis, Axel H. Schönthal, Thomas C. Chen, Florence M. Hofman

Research output: Contribution to journalArticlepeer-review

24 Scopus citations


Our laboratory has previously shown that a novel compound, 2,5-dimethyl-celecoxib (DMC), which is structurally similar to the cyclooxygenase-2 (COX-2) inhibitor celecoxib but lacks the COX-2-inhibitory function, mimics the antitumor effects of celecoxib. Most studies on DMC, however, focused on its effects on tumor cells. Here, we investigated the activities of DMC as an antiangiogenic agent in both in vitro and in vivo systems. Using primary cultures of human glioma specimens, we found that DMC treatment was cytotoxic to tumor-associated brain endothelial cells (TuBEC), which was mediated through the endoplasmic reticulum stress pathway. In contrast, confluent cultures of quiescent human BEC did not undergo cell death. DMC potently suppressed the proliferation and migration of the TuBEC. DMC caused no apparent effects on the secretion of vascular endothelial growth factor and interleukin-8 but inhibited the secretion of endothelin-1 in tumor-associated EC. DMC treatment of glioma xenografts in mice resulted in smaller tumors with a pronounced reduction in microvessel density compared with untreated mice. In vitro and in vivo analyses confirmed that DMC has antivascular activity. Considering that DMC targets both tumor cells and tumor-associated ECs, this agent is a promising anticancer drug.

Original languageEnglish (US)
Pages (from-to)631-641
Number of pages11
JournalMolecular Cancer Therapeutics
Issue number3
StatePublished - Mar 2010
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Antiangiogenic activities of 2,5-dimethyl-celecoxib on the tumor vasculature'. Together they form a unique fingerprint.

Cite this